165 related articles for article (PubMed ID: 35026215)
1. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond.
Soleimani A; Dadjoo P; Avan A; Soleimanpour S; Rajabian M; Ferns G; Ryzhikov M; Khazaei M; Hassanian SM
Life Sci; 2022 Mar; 293():120050. PubMed ID: 35026215
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma.
Attia S; Atwan N; Arafa M; Shahin RA
Pathologica; 2019 Mar; 111(1):18-23. PubMed ID: 31217618
[TBL] [Abstract][Full Text] [Related]
3. CD133+/CD166+ human gastric adenocarcinoma cells present the properties of neoplastic stem cells and emerge more malignant features.
Ni T; Wang H; Zhan D; Tao L; Lv M; Wang W; Chu Z; Zhou Z; Sunagawa M; Liu Y
Life Sci; 2021 Mar; 269():119021. PubMed ID: 33450261
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
5. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
7. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer.
Jia ZF; Wu YH; Cao DH; Cao XY; Jiang J; Zhou BS
Future Oncol; 2017 May; 13(11):979-989. PubMed ID: 28326835
[TBL] [Abstract][Full Text] [Related]
10. Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines.
Moon Y; Kim D; Sohn H; Lim W
Clin Exp Metastasis; 2016 Jun; 33(5):487-96. PubMed ID: 27137188
[TBL] [Abstract][Full Text] [Related]
11. Cancerous and non-neoplastic stem cells in the stomach similarly express CD44 and CD133.
Feitosa NPP; Pereira VBM; Silva BGB; Queroz AVF; Rodrigues BJ; Costa MLV; Alencar CH; Lima-Júnior RCP; Wong DVT; Frota CC; Almeida PRC
Acta Histochem; 2021 Oct; 123(7):151787. PubMed ID: 34517259
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subpopulation of long-term tumor-initiating cells in colon cancer.
Peng L; Xiong Y; Wang R; Xiang L; Zhou H; Gu H
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729895
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating CD133(+) cells in patients with gastric cancer.
Xia P; Song CL; Liu JF; Wang D; Xu XY
Cell Prolif; 2015 Jun; 48(3):311-7. PubMed ID: 25727099
[TBL] [Abstract][Full Text] [Related]
14. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W
Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843
[TBL] [Abstract][Full Text] [Related]
15. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer.
Akbari M; Shomali N; Faraji A; Shanehbandi D; Asadi M; Mokhtarzadeh A; Shabani A; Baradaran B
Cell Biol Int; 2020 Feb; 44(2):368-380. PubMed ID: 31579983
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.
Lu L; Wu M; Sun L; Li W; Fu W; Zhang X; Liu T
Medicine (Baltimore); 2016 Oct; 95(42):e5163. PubMed ID: 27759647
[TBL] [Abstract][Full Text] [Related]
17. Sequential expression of putative stem cell markers in gastric carcinogenesis.
Wang T; Ong CW; Shi J; Srivastava S; Yan B; Cheng CL; Yong WP; Chan SL; Yeoh KG; Iacopetta B; Salto-Tellez M
Br J Cancer; 2011 Aug; 105(5):658-65. PubMed ID: 21829201
[TBL] [Abstract][Full Text] [Related]
18. Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer.
Wattanawongdon W; Bathpho TS; Tongtawee T
Turk J Gastroenterol; 2021 Mar; 32(3):261-268. PubMed ID: 34160355
[TBL] [Abstract][Full Text] [Related]
19. DKK3 attenuates the cytotoxic effect of natural killer cells on CD133
Xia P; Xu XY
Mol Carcinog; 2017 Jul; 56(7):1712-1721. PubMed ID: 28218426
[TBL] [Abstract][Full Text] [Related]
20. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
